arrow
L

Larysa Sanchez

ica hn school of medicine at mount sinai
H指数:17
被引数:1,207

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma

基线绝对淋巴细胞计数、C反应蛋白和铁蛋白可预测多发性骨髓瘤中CAR T细胞相关毒性和结局。

2026-03-300
PRE
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression

Cilta-Cel治疗多发性骨髓瘤后的长期缓解与多样化的T细胞和较低的髓系抑制相关

2025-11-070
OAAI
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma

髓外疾病而非骨旁疾病预示着CAR T细胞疗法在多发性骨髓瘤中的不良结局。

2025-05-030
PRE
A Phase 2 Study of Daratumumab in Combination with Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

一项关于达鲁珠单抗联合减量硼替佐米、来那度胺和地塞米松在移植不适宜的老年新诊断多发性骨髓瘤患者中的2期研究

BLOOD
IF23.1
2024-11-050
PRE
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
2024-09-162
OAAI
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
2024-01-093
OAAI
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
2023-03-2126
OAAI
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone
2021-07-125
OAAI
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2
2019-12-220
OAAI